Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06619444 · ClinicalTrials.gov registry record · NA
Dose-Response to Resistance Exercise on Cardiovascular Health
A NA study of Cardiovascular Risk, sponsored by University of Pittsburgh.
- Recruiting
- Registry status
- NA
- Development phase
- 240
- Enrollment target
- 1
- Study location
NCT06619444: Recruiting NA study of Cardiovascular Risk, sponsored by University of Pittsburgh.
NCT06619444 is a NA study of Cardiovascular Risk that is actively recruiting participants, run by University of Pittsburgh. The registered enrollment target is 240 participants, below the 7,120-participant average among 5 other Cardiovascular Risk trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06619444, a NA study of Cardiovascular Risk, is actively recruiting participants, sponsored by University of Pittsburgh.
- RECRUITING
- Registry status
- NA
- Development phase
- 240 participants
- Enrollment target
- 1
- Study location
Study Summary
A large body of evidence indicates numerous health benefits of physical activity, including prevention of cardiovascular disease (CVD), the leading cause of death in the US. This evidence has led to US Physical Activity Guidelines that recommend ≥150 min/week of moderate or ≥75 min/week of vigorous aerobic exercise (AE), plus resistance exercise (RE; such as weight lifting) on ≥2 days/week. To date, current research has mostly focused on AE, and we know a great deal about the dose-response relation between AE and health, resulting in clear and practical guidance to the public on the recommended "dose" in min/week. However, currently far less is known about the dose-response for RE: ≥2 days/week are recommended, but with no duration specified. Thus, this project aims to provide clarity on the dose relationship between RE and health. This project will significantly contribute to developing more effective CVD prevention approaches, advancing prescriptive intervention guidelines, by helping to fill the important gaps in knowledge on effective minimum dose, beneficial optimal dose, and safe maximum dose of RE for CVD prevention. Thus, advancing prescriptive intervention guidelines, and provide important insights for future science of physical activity and health.
Primary Outcome
The primary outcome will be change from baseline to 6 months in the average composite cardiovascular disease (CVD) risk z-score comprising systolic Blood pressure (SBP), Low-Density lipoprotein cholesterol (LDL-C), fasting glucose, and percent body fat; lower scores indicate better overall CVD risk profile. Each CVD risk factor at baseline and 6 months will be individually standardized to sex-specific z -scores with a mean of 0 and standard deviation (SD) of 1 based on the formula (observed valu
Conditions Studied
Interventions
- BEHAVIORAL Aerobic exercise only
- BEHAVIORAL 30 min of resistance exercise
- BEHAVIORAL 60 min of resistance exercise
- BEHAVIORAL 120 min of resistance exercise
Study Locations (1)
Pennsylvania
- Physical Activity Research Center (PARC) - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2024-12-03 |
| Est. Completion | 2027-12 |
| Phase | NA |
What NCT06619444 shows while recruiting
NCT06619444 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, below the 7,120-participant average among 5 other Cardiovascular Risk trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Cardiovascular Risk appearing as the primary indexed condition, and to 4 interventions - of which Aerobic exercise only is the first listed.
NCT06619444 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06619444 about?
NCT06619444 is a clinical study titled "Dose-Response to Resistance Exercise on Cardiovascular Health". A large body of evidence indicates numerous health benefits of physical activity, including prevention of cardiovascular disease (CVD), the leading cause of death in the US. This evidence has led to US Physical Activity Guidelines that recommend ≥150 min/week of moderate or ≥75 min/week of vigorous ...
What is the current status of trial NCT06619444?
This trial is currently recruiting. It is a NA study. The enrollment target is 240 participants. The study started on 2024-12-03. Estimated completion is 2027-12.
What conditions does trial NCT06619444 study?
This clinical trial studies the following conditions: Cardiovascular Risk.
What interventions are being tested in trial NCT06619444?
The interventions under investigation include: Aerobic exercise only (BEHAVIORAL), 30 min of resistance exercise (BEHAVIORAL), 60 min of resistance exercise (BEHAVIORAL), 120 min of resistance exercise (BEHAVIORAL).
Who is sponsoring clinical trial NCT06619444?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06619444 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Risk
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Impact of the Corrie Lipids Digital Health Program on Lipid Optimization
RECRUITING · NA
-
Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM)
RECRUITING
-
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
RECRUITING · Phase 3
-
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation
ACTIVE NOT RECRUITING · Phase 3
-
Levels of Inflammation in People With Cardiovascular Disease (POSEIDON)
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI